Abstract:Background: Atopic dermatitis (AD) is a highly prevalent inflammatory skin disorder characterized by episodic exacerbations and remissions. Why the clinically healthy skin of AD patients becomes rapidly inflamed and very pruritic is poorly understood. Objective: To investigate cowhage- and histamine-induced itch and skin expression levels of their target receptors in lesional and non-lesional skin of AD, compared to the skin of patients with psoriasis, chronic spontaneous urticaria (CSU) and healthy subjects. Methods: Patients with AD, psoriasis and chronic spontaneous urticaria (CSU) as well as healthy control subjects (HC) (n = 20 each) were assessed for differences in itch parameters, neurogenic flare reaction and local blood flow responses to skin provocations with cowhage and histamine. Skin biopsies from 10 AD, 10 psoriasis,11 CSU and 12 HC were obtained to assess expression of protease-activated receptors 2 and 4 (PAR-2, PAR-4), histamine H1 and H4 receptors (H1R, H4R), and mast cells. Results: Provocation of non-lesional skin of AD patients with cowhage resulted in prolonged itch (p = 0.020), which was not observed in psoriasis and CSU. Significantly prolonged and more intense cowhage- and histamine-induced itch (for duration, peak and overall intensity) was also observed in lesional AD skin. Diminished neurogenic flare reaction and blood flow after histamine provocation were shown in AD and psoriasis patients. Non-lesional AD skin along with lesional AD and psoriasis skin showed an increased expression of PAR-2 and PAR-4, H1R and H4R. Mast cell number was higher in lesional AD and psoriasis skin (p = 0.006 and p = 0.006, respectively). Conclusion: The non-lesional skin of AD patients markedly differs from healthy skin in cowhage-induced itch responses and the expression of receptors for proteases and histamine. Proactive therapeutic interventions that downregulate these receptors may prevent episodic exacerbation in AD.

Cutaneous nerve morphology and protease activated receptor 2 expression in pruritic skin lesions of atopic dermatitis

Myeloid Dendritic Cells Are Increased in the Lesional Skin and Associated with Pruritus in Patients with Prurigo Nodularis

Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis

RNA Sequencing Reveals the Transcriptome Profile of the Atopic Prurigo Nodularis with Severe Itching

PAR2 Mediates Itch via TRPV3 Signaling in Keratinocytes

Transcriptomic, Epigenomic, and Neuroanatomic Signatures Differ in Chronic Prurigo, Atopic Dermatitis, and Brachioradial Pruritus

Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo

Quantification of nerve fibers and their contact with Langerhans cells in the lesional skin of neurodermatitis

Clinically uninvolved but not healthy-The skin of patients with atopic dermatitis is primed for itch and inflammation

Cutaneous Components Leading to Pruritus, Pain, and Neurosensitivity in Atopic Dermatitis: A Narrative Review

Pathophysiological function of proteinase activated receptor 2 in skin

Association between atopic dermatitis and prurigo nodularis: a systematic review and meta‐analysis

Molecular Mechanisms of Pruritus in Prurigo Nodularis

Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus.

Tryptase and Protease-Activated Receptor-2 Stimulate Scratching Behavior in a Murine Model of Ovalbumin-Induced Atopic-Like Dermatitis

Propionate alleviates itch in murine models of atopic dermatitis by modulating sensory TRP channels of dorsal root ganglion

Effects of Tacrolimus on the Expression of Proteinase Activated Receptor 2 in Lesions of Atopic Dermatitis

New insight into prurigo nodularis: Proadrenomedullin N‐terminal 20 peptide mediates mouse mast cell activation via Mrgprb2

Research progress in neuroimmune disorders in atopic dermatitis

Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis

508 - Dupilumab treatment normalizes intraepidermal nerve fiber density in patients with moderate-to-severe AD